BioCheetah Pte Ltd

 BioCheetah Pte Ltd (Co. Reg. No. 201803287H) is a Singapore-based, A*STAR-IMCB spin-off diagnostics company. It is primarily set up to develop and commercialize non-invasive, protein-based diagnostic applications. First diagnostic applications in development are based on the proprietary bladder cancer biomarkers and detection antibodies discovered and developed in IMCB by BioCheetah’s Scientific Founder (Prof. Jean-Paul Thiery) and the co-Founder/Chief Executive Officer (Dr. Kian-Chung Lee). Both Intellectual Property of bladder cancer biomarkers and detection antibodies are licensed from A*STAR. Products to be developed include professional use in-vitro diagnostic ELISA and Point-of-care test (POCT) kits. The kits will employ a novel multiplex urine-based biomarkers panel with high sensitivity and specificity for diagnosis and monitoring of bladder cancer. BioCheetah’s target markets are to encompass local and overseas public and private healthcare providers. BioCheetah is in the midst of building an ISO 13485 production facility at Block 79, JTC LaunchPad in Singapore, setting up its Quality Management System (QMS) for the purpose of development and manufacturing of its diagnostic products as well as in discussion with SingHealth and overseas hospitals for clinical validation of the to-be-developed bladder cancer diagnostic products.


Nominated by

Senior Director, Business Development,
JETRO Singapore
 BioCheetah Pte Ltd was setup last year but already obtained 3 different grants from Enterprise Singapore - Proof of Value, Proof of Concept and Enterprise Development Grant. The strong support shows the promising potential of BioCheetah after Enterprise Singapore arranged a panel of industry experts plus their own internal experts to review the company.
In a very short time, the company has already built up a ISO 13485 facilities and will undergo ISO audit this or next quarter. It is probably one of the fastest growing medtech company in Singapore right now.